Liminatus Pharma, Inc. (LIMN): Net Income

Annual figures by period end, from SEC filings.

-$10.21M

Year ended 2025-12-31

-$12.52M

Trailing 12 months to 2026-06-30

2024-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$10.21M	n/m	2026-03-31, From 2025-01-01
2024-12-31	-$3.55M	n/a	2026-03-31, From 2024-01-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Liminatus Pharma, Inc. (LIMN)	2025-12-31	-$10.21M	n/m
Adaptin Bio, Inc. (APTN)	2025-12-31	-$5.17M	n/m
Brainstorm Cell Therapeutics Inc. (BCLI)	2025-12-31	-$10.31M	n/m
Abpro Holdings, Inc. (ABPO)	2025-12-31	-$2.89M	n/m
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	-$5.52M	n/m
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	-$13.38M	n/m
Estrella Immunopharma, Inc. (ESLA)	2025-12-31	-$13.06M	n/a
BioCardia, Inc. (BCDA)	2025-12-31	-$8.23M	n/m
Cero Therapeutics Holdings, Inc. (CERO)	2025-12-31	-$19.92M	n/a

Compare LIMN, APTN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗